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Background
Vasopressin is commonly used as an adjunct to catecholamines to support blood pres-
sure in refractory septic shock, but its effect on mortality is unknown. We hypothe-
sized that low-dose vasopressin as compared with norepinephrine would decrease 
mortality among patients with septic shock who were being treated with conventional 
(catecholamine) vasopressors.
Methods
In this multicenter, randomized, double-blind trial, we assigned patients who had 
septic shock and were receiving a minimum of 5 μg of norepinephrine per minute to 
receive either low-dose vasopressin (0.01 to 0.03 U per minute) or norepinephrine (5 to 
15 μg per minute) in addition to open-label vasopressors. All vasopressor infusions 
were titrated and tapered according to protocols to maintain a target blood pressure. 
The primary end point was the mortality rate 28 days after the start of infusions.
Results
A total of 778 patients underwent randomization, were infused with the study drug 
(396 patients received vasopressin, and 382 norepinephrine), and were included in the 
analysis. There was no significant difference between the vasopressin and norepineph-
rine groups in the 28-day mortality rate (35.4% and 39.3%, respectively; P = 0.26) or 
in 90-day mortality (43.9% and 49.6%, respectively; P = 0.11). There were no signifi-
cant differences in the overall rates of serious adverse events (10.3% and 10.5%, re-
spectively; P = 1.00). In the prospectively defined stratum of less severe septic shock, 
the mortality rate was lower in the vasopressin group than in the norepinephrine 
group at 28 days (26.5% vs. 35.7%, P = 0.05); in the stratum of more severe septic shock, 
there was no significant difference in 28-day mortality (44.0% and 42.5%, respec-
tively; P = 0.76). A test for heterogeneity between these two study strata was not sig-
nificant (P = 0.10).
Conclusions
Low-dose vasopressin did not reduce mortality rates as compared with norepineph-
rine among patients with septic shock who were treated with catecholamine vaso-
pressors. (Current Controlled Trials number, ISRCTN94845869.)
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Septic shock is the most common cause of death in intensive care units (ICUs)1,2 and has a mortality rate of 40 to 60%.2,3 Re-
suscitation strategies include the administration of 
intravenous fluids and the use of catecholamines 
such as norepinephrine, epinephrine, dopamine, 
and dobutamine.4,5 Although largely effective in 
reestablishing minimally acceptable mean arterial 
pressures to maintain organ perfusion, catechol-
amines have important adverse effects and may 
even increase mortality rates.6 For example, nor-
epinephrine, a potent and commonly used α-adren-
ergic agent in cases of septic shock, may decrease 
cardiac output, oxygen delivery, and blood flow 
to vulnerable organs despite adequate perfusion 
pressure.7
Vasopressin, an endogenously released peptide 
hormone, has emerged as an adjunct to catechol-
amines for patients who have severe septic shock. 
The rationale for its use is the relative vasopressin 
deficiency in patients with septic shock and the 
hypothesis that exogenously administered vaso-
pressin can restore vascular tone and blood pres-
sure, thereby reducing the need for the use of cat-
echolamines.8-10 Observational studies involving 
the use of vasopressin infusion rates below 0.1 U 
per minute in patients with vasodilatory shock 
have repeatedly shown improved short-term blood-
pressure responses.10-14 However, vasopressin in-
fusion may decrease blood flow in the heart, kid-
neys, and intestine. Despite the widespread use of 
vasopressin in clinical practice, only two small 
randomized trials have evaluated its use in pa-
tients who had septic shock.10,12 Vasopressin in-
creased blood pressure, decreased catecholamine 
requirements, and improved renal function as 
compared with a control agent. However, neither 
of the trials was powered to evaluate mortality, 
organ dysfunction, or safety.
To address these uncertainties, we conducted 
a multicenter, randomized, stratified, double-blind 
trial among patients who had septic shock and 
were receiving usual care (including catechol-
amines), to determine whether vasopressin de-
creased 28-day mortality, as compared with nor-
epinephrine. Our secondary hypothesis was that 
the beneficial effects of vasopressin would be more 
pronounced than those of norepinephrine in the 
subgroup of patients with more severe (as opposed 
to less severe) septic shock. Therefore, we strati-
fied patients at the time of randomization accord-
ing to the baseline dose of norepinephrine.
Me thods
This trial was conducted between July 2001 and 
April 2006 in 27 centers in Canada, Australia, and 
the United States and was approved by the re-
search ethics boards of all participating institu-
tions. Written informed consent was obtained from 
all patients, their next of kin, or another surro-
gate decision maker, as appropriate. The data were 
collected by the investigators and analyzed by the 
data management committee. The executive com-
mittee vouches for the accuracy and completeness 
of the data and analysis. The article was written 
by the writing committee, and the decision to 
publish was made by the executive committee. 
Full details of the trial protocol can be found in 
the Supplementary Appendix, available with the 
full text of this article at www.nejm.org.
Study Patients
Patients older than 16 years of age who had sep-
tic shock that was resistant to fluids (as defined 
by lack of response to 500 ml of normal saline or 
a requirement for vasopressors [see the Supple-
mentary Appendix]) and low-dose norepinephrine 
were considered for enrollment. Septic shock was 
defined by the presence of two or more diagnos-
tic criteria for the systemic inflammatory response 
syndrome,15 proven or suspected infection, new 
dysfunction of at least one organ, and hypotension 
despite adequate fluid resuscitation (requiring va-
sopressor support consisting of at least 5 μg of 
norepinephrine or the equivalent per minute [see 
the Supplementary Appendix] for 6 hours). Exclu-
sion criteria are listed in the Supplementary Ap-
pendix.
Treatment Assignments
Treatment with either vasopressin or norepineph-
rine was assigned by means of a central telephone 
randomization system accessed by the study phar-
macists at the participating institutions. A com-
puter-generated randomization list of variable per-
muted blocks of 2, 4, and 6 was used for treatment 
allocation, which was stratified by center and by 
severity of shock in the hour before randomiza-
tion (the stratum of less severe septic shock was 
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defined as treatment with 5 to 14 μg of norepi-
nephrine or the equivalent per minute, and the stra-
tum of more severe septic shock was defined as 
treatment with 15 μg or more of norepinephrine 
or the equivalent per minute). Infusions of both 
study drugs were prepared locally by study phar-
macists who were aware of the two treatments. All 
other clinical staff, investigators, research per-
sonnel, patients, and families were unaware of the 
treatment assignments for the duration of the 
trial.
Drug Infusion
Vasopressin (30 U) and norepinephrine (15 mg) 
were mixed in identical 250-ml intravenous bags 
of 5% dextrose in water, with final concentrations 
of 0.12 U of vasopressin per milliliter and 60 μg 
of norepinephrine per milliliter. The study-drug 
infusion was started at 5 ml per hour and increased 
by 2.5 ml per hour every 10 minutes during the 
first hour to achieve a constant target rate of 15 ml 
per hour. Thus, the blinded vasopressin infusion 
was started at 0.01 U per minute and titrated to a 
maximum of 0.03 U per minute, whereas the blind-
ed norepinephrine infusion was started at 5 μg per 
minute and titrated to a maximum of 15 μg per 
minute.
During the initiation and titration of the study 
drug, the bedside nurse also titrated open-label 
vasopressors to maintain a constant target mean 
arterial pressure. An initial target mean arterial 
pressure of 65 to 75 mm Hg was recommended; 
however, the attending ICU physician could mod-
ify the target blood pressure of each patient.
Open-label vasopressors were increased only if 
the target mean arterial pressure was not reached 
on maximal study-drug infusion. Tapering of 
open-label vasopressors was permitted only when 
the target mean arterial pressure had been reached 
during the study-drug infusion. Tapering of the 
study drug was commenced only when the target 
mean arterial pressure had been maintained for 
8 hours without any open-label vasopressors. In-
fusion of the study drug was continued at 15 ml 
per hour until the patient died, a serious adverse 
event occurred, or the patient’s condition improved 
to the extent that open-label vasopressors were no 
longer required. Neither crossover to the other 
group nor open-label vasopressin was permitted.
The study-drug infusion was discontinued or 
interrupted if any of the following predetermined 
serious adverse events occurred: acute ST-segment 
elevation confirmed by a 12-lead electrocardio-
gram, serious or life-threatening (hemodynam-
ically unstable) cardiac arrhythmias, acute mesen-
teric ischemia, digital ischemia, or hyponatremia 
(serum sodium level, <130 mmol per liter). If the 
clinical team noted an adverse event that they con-
sidered to be related to the study drug, then the 
study drug was discontinued for at least 8 hours 
and a serious adverse event was reported. The 
study drug could be restarted if, in the judgment 
of the investigator or attending physician, the ad-
verse event had been treated, the condition had 
been reversed, and the event was not thought to 
have been a result of the study drug or study pro-
tocol.
If vasopressor support was required during the 
same admission to the ICU after a patient had 
been weaned from the study drug, the study drug 
was preferentially reinfused, as long as no exclu-
sion criteria were met. In a subgroup of patients 
at six of the participating institutions, plasma was 
collected for measurement of circulating vasopres-
sin levels (see the Supplementary Appendix). 
End Points 
The primary outcome was death from any cause 
and was assessed 28 days after the start of infu-
sions. Secondary outcomes included 90-day mor-
tality; days alive and free of organ dysfunction dur-
ing the first 28 days according to the Brussels 
criteria16 (see the Supplementary Appendix); days 
alive and free of vasopressor use, mechanical ven-
tilation, or renal replacement therapy; days alive 
and free of the systemic inflammatory response 
syndrome, defined as freedom from two or more 
of the four diagnostic criteria for the systemic in-
flammatory response syndrome; days alive and free 
of corticosteroid use; and length of stay in the 
ICU and hospital. We also evaluated rates of seri-
ous adverse events.
Statistical Analysis
We calculated that 776 patients were required for 
enrollment, randomization, and receipt of the study 
drug in order to detect an absolute 10% difference 
in mortality, assuming a mortality rate of 60% in 
the norepinephrine group and a two-sided alpha 
error of 0.05 and a power of 80%. An independent 
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data and safety monitoring committee evaluated 
two preplanned interim analyses, after 194 patients 
had been enrolled and after 388 patients had been 
enrolled. An O’Brien–Fleming approach was used 
for sequential stopping rules for safety and effi-
cacy according to the Lan–DeMets method.17 Af-
ter both interim analyses, the data and safety mon-
itoring committee recommended that the study 
be continued without protocol modification.
Midway through the trial, the executive com-
mittee, unaware of all data and in conference with 
the data and safety monitoring committee, deter-
mined that patients who had undergone random-
ization but had never received an infusion would 
not be included in the primary analysis, since their 
omission would be equally distributed between 
groups, would be unrelated to treatment assign-
ment, and would not bias outcome ascertain-
ment.18 We increased the total number of patients 
enrolled to maintain the target sample size after 
the removal of such patients from the analysis.
The primary analysis, which compared 28-day 
mortality between the two treatment groups, was 
performed with the use of an unadjusted chi-
square test, and all patients were assessed accord-
ing to the treatment received and to the treatment 
group assigned at randomization. Results are pre-
sented as absolute and relative risks and 95% 
confidence intervals. Kaplan–Meier curves for the 
estimated probability of survival in the two treat-
ment groups as a function of time from enrollment 
in the study were compared with the use of the 
log-rank test.
Because of the complex nature of septic shock 
and to account for any imbalances between the 
two treatment groups at baseline, a logistic-regres-
sion procedure and significant covariates that 
predicted outcomes were used to adjust raw values 
for 28-day mortality. Age, illness severity (score on 
the Acute Physiology and Chronic Health Evalu-
ation [APACHE II] at baseline), serious coexisting 
conditions, and other baseline covariates that pre-
dicted outcome (at a threshold P value of 0.20) 
were entered into the model. Results are presented 
as odds ratios and 95% confidence intervals. We 
used parametric procedures (independent t-test), 
nonparametric procedures (Wilcoxon rank-sum 
test), or Fisher’s exact test to compare all second-
ary outcomes.
Patients were also assessed according to the 
a priori strata of more severe or less severe septic 
shock (as defined by the dose of norepinephrine) 
as well as in several exploratory analyses of shock 
severity defined by post hoc criteria. The treatment 
effect within each subgroup was assessed accord-
ing to the within-stratum analysis, with the use 
of the chi-square test. We also used logistic-regres-
sion analysis to test for an interaction between 
stratum and treatment in order to determine 
whether there was a differential effect on mor-
tality.
The data analyst and investigators remained 
unaware of the treatment assignments while un-
dertaking the final analyses. Analysis was con-
ducted with the use of SAS software (version 9.1.3), 
and all P values were two-sided.
R esult s
Of 6229 screened patients, 802 underwent random-
ization after providing informed consent (Fig. 1). 
Of these 802 patients, 2 withdrew consent after 
infusion of the study drug and 21 did not receive 
the infusion for various reasons. In addition, one 
patient was lost to follow-up before day 28. Thus 
779 patients underwent randomization and infu-
sion of the study drug, and 778 were included in 
the final primary analysis: 396 in the vasopressin 
group and 382 in the norepinephrine group (Fig. 
1). The baseline characteristics of the two groups 
are shown in Table 1. Enrolled patients were se-
verely ill, as indicated by the APACHE II scores,19 
by the proportion with new organ dysfunction, by 
the serum lactate levels, and by the norepinephrine 
infusion rates at study entry.
Blood pressure in the two treatment groups was 
similar throughout the study, whereas the heart 
rate was significantly lower in the vasopressin 
group than in the norepinephrine group during 
the first 4 days of treatment (P<0.001) (Fig. 1 in 
the Supplementary Appendix). The difference in 
the mean infusion rates of the study drug between 
treatment groups during the first 5 days was 
within 2 ml per hour. The rate of norepinephrine 
infusion was significantly lower in the vasopres-
sin group than in the norepinephrine group dur-
ing the first 4 days (P<0.001) (Fig. 2 in the Sup-
plementary Appendix).
There was no significant difference in the pri-
mary outcome (rate of death from any cause, 
assessed 28 days after the start of infusions), be-
tween the vasopressin group and the norepineph-
rine group (35.4% and 39.3%, respectively; P = 0.26; 
95% confidence interval [CI] for absolute risk re-
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duction in the vasopressin group, −2.9 to 10.7%) 
(Table 2 and Fig. 2). Similarly, there was no sig-
nificant difference in mortality at 90 days (43.9% 
and 49.6%, respectively; P = 0.11; 95% CI for abso-
lute risk reduction, −1.3 to 12.8%) or in rates of 
organ dysfunction (Table 2). The results remained 
nonsignificant after multivariate logistic-regres-
sion analysis (odds ratio for death in the vasopres-
33p9
802 Underwent randomization
6229 Patients were assessed for eligibility
5427 Were not enrolled
3758 (69.2%) Met specific exclusion criteria
13.9% >24 Hr had elapsed
12.8% Had unstable coronary syndrome
10.1% Received open-label vasopressin
7.8% Had cancer or other irreversible
disease with >50% 6-mo mortality
6.2% Had acute mesenteric ischemia
4.8% Were expected to die within 12 hr
4.8% Did not get commitment from
physician for aggressive care
4.7% Had chronic heart disease 
(NYHA III or IV)
2.1% Had severe hyponatremia
1.4% Had traumatic brain injury
0.5% Had Raynaud’s syndrome
0.2% Were pregnant
1669 (30.8%) Had other reasons
12.3% Had improving condition
5.6% Could not contact next of kin
4.6% Had other reasons
3.6% Declined to participate
3.0% Were enrolled in another study
1.7% Did not receive physician approval
396 Were assigned to receive norepinephrine
13 Did not undergo infusion
6 Had acute myocardial infarction 
or elevated troponin level
3 Had norepinephrine requirements  
drop to <5 µg/min
2 Went to operating room, >24 hr had
elapsed 
1 Received open-label vasopressin
1 Died
406 Were assigned to receive vasopressin
8 Did not undergo infusion
5 Had norepinephrine requirements drop
to <5 µg/min
2 Had acute myocardial infarction 
or elevated troponin level
1 Was withdrawn from care
1 Withdrew consent
1 Was lost to follow-up
1 Withdrew consent
383 Underwent infusion 398 Underwent infusion
382 Were assessed 396 Were assessed
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Figure 1. Enrollment and Outcomes.
NYHA denotes New York Heart Association classification.
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Table 1. Demographic and Baseline Characteristics of the Patients.* 
Characteristic
Norepinephrine Group 
(N = 382)
Vasopressin Group  
(N = 397) P Value
Age — yr 61.8±16 59.3±16.4 0.03
Male sex — no. (%) 229 (59.9) 246 (62.0) 0.56
Recent surgical history — no. (%) 132 (34.6) 151 (38.0) 0.31
Elective 8 (2.1) 6 (1.5)
Emergency 124 (32.5) 145 (36.5)
APACHE II score 27.1±6.9 27.0±7.7 0.84
White race — no. (%)† 320 (83.8) 336 (84.6) 0.97
Preexisting conditions — no. (%)
Ischemic heart disease 65 (17.0) 68 (17.1) 0.62
Congestive heart failure 30 (7.9) 28 (7.1) 0.56
Chronic obstructive pulmonary disease 72 (18.8) 55 (13.9) 0.11
Chronic renal failure 48 (12.6) 40 (10.1) 0.34
Diabetes 88 (23.0) 77 (19.4) 0.29
Liver disease 36 (9.4) 52 (13.1) 0.16
Alcoholism 53 (13.9) 55 (13.9) 0.62
Injection-drug abuse 14 (3.7) 20 (5.0) 0.40
Cancer 104 (27.2) 85 (21.4) 0.11
Compromised immune system 72 (18.8) 67 (16.9) 0.48
Solid-organ transplant 17 (4.5) 14 (3.5) 0.50
Corticosteroid use 86 (22.5) 82 (20.7) 0.51
Recent trauma 16 (4.2) 23 (5.8) 0.30
New organ failure — no. (%)
Cardiovascular 382 (100) 397 (100) 1.00
Respiratory 341 (89.3) 342 (86.1) 0.15
Renal 258 (67.5) 264 (66.5) 0.68
Hematologic and coagulation 84 (22.0) 118 (29.7) 0.02
Neurologic 89 (23.3) 101 (25.4) 0.48
No. of organ dysfunctions 3.4±1.1 3.5±1.1 0.04
Source of infection — no. (%) 0.77
Lung 165 (43.2) 162 (40.8)
Abdomen 100 (26.2) 111 (28.0)
Other‡ 117 (30.6) 124 (31.2)
Pathogen type in cultures — no. (%) 0.19
Gram-positive alone 59 (15.4) 80 (20.2)
Gram-negative alone 43 (11.3) 40 (10.1)
Mixed organisms 139 (36.4) 143 (36.0)
Other 51 (13.4) 62 (15.6)
No pathogen 90 (23.6) 72 (18.1)
Hemodynamic variables
Systolic blood pressure — mm Hg 110±17 108±17 0.10
Mean arterial pressure — mm Hg 73±10 72±9 0.23
Arterial pH 7.31±0.1 7.32±0.1 0.71
Serum lactate level — mmol/liter 3.5±3.0 3.5±3.2 0.96
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sin group at 28 days, 0.88 [95% CI, 0.62 to 1.26]; 
odds ratio for death at 90 days, 0.81 [95% CI, 
0.57 to 1.16]).
There were no significant differences in the 
overall rates or specific categories of serious ad-
verse events between the vasopressin and norepi-
nephrine groups (overall rates, 10.3% and 10.5%, 
respectively; P = 1.00) (Table 3). There was a trend 
toward a higher rate of cardiac arrest in the nor-
epinephrine group than in the vasopressin group 
(2.1% vs. 0.8%, P = 0.14) and a trend toward a 
higher rate of digital ischemia in the vasopressin 
group than in the norepinephrine group (2.0% vs. 
0.5%, P = 0.11).
In the subgroup of patients in whom plasma 
vasopressin levels were measured, the levels were 
extremely low at baseline (median, 3.2 pmol per 
liter; interquartile range, 1.7 to 4.9). These levels 
did not change in the norepinephrine group. In-
fusion of low-dose vasopressin increased vasopres-
sin levels to medians of 73.6 pmol per liter (inter-
quartile range, 58.6 to 94.7) at 6 hours and 98.0 
pmol per liter (interquartile range, 67.1 to 127.8) at 
24 hours (Fig. 3 in the Supplementary Appendix).
Baseline characteristics of the patients in the 
stratum of more severe septic shock and those in 
the stratum of less severe septic shock are pre-
sented in the Supplementary Appendix. Among 
patients who had less severe septic shock (an in-
fusion of 5 to 14 μg of norepinephrine per min-
ute at randomization), there were trends in favor 
of the vasopressin group with respect to both 
28-day and 90-day mortality (Table 4). In contrast, 
there were no significant differences in mortal-
ity between the vasopressin and norepinephrine 
groups in the stratum of more severe septic shock. 
However, the test for the interaction between the 
treatment assignment and the severity-of-shock 
subgroup was not significant (P = 0.10). We per-
formed several additional post hoc analyses of the 
results stratified according to different indicators 
of illness severity (Table 3 of the Supplementary 
Table 1. (Continued.) 
Characteristic
Norepinephrine Group 
(N = 382)
Vasopressin Group  
(N = 397) P Value
Vasoactive drug dosage at randomization§
Norepinephrine — μg/min (μg/kg/min) 20.7±18.1 (0.28±0.26) 20.7±22.1 (0.26±0.27) 0.97
Epinephrine — μg/min (μg/kg/min) 8.6±9.4 (0.12±0.15) 14.6±16.9 (0.20±0.29) 0.12
Dopamine — μg/kg/min 7.3±5.3 7.6±6.4 0.88
Dobutamine — μg/kg/min 5.1±3.7 6.4±5.2 0.18
Milrinone — μg/kg/min 0.4±0.3 0.3±0.1 0.23
Phenylephrine — μg/min (μg/kg/min) 151±74 (2.03±1.17) 157±90 (2.04±1.31) 0.61
Vasoactive drug infusions — no. (%)
Norepinephrine alone 222 (58.1) 224 (56.4) 0.63
No norepinephrine 53 (13.9) 53 (13.4) 0.83
Two or more vasopressors 111 (29.1) 124 (31.2) 0.51
Other therapy for sepsis — no. (%)
Corticosteroids 293 (76.7) 296 (74.6) 0.49
Activated protein C 56 (14.7) 61 (15.4) 0.78
Baseline tidal volume — ml/kg 7.4±2.5 7.2±2.5 0.43
Time from meeting inclusion criteria to study-drug  
infusion — hr
11.5±9.4 11.9±8.9 0.57
* Plus–minus values are means ±SD. APACHE II denotes Acute Physiology and Chronic Health Evaluation II.19
† Race was determined by the local study coordinators.
‡ Other sources of infection included blood, skin, central nervous system, bones and joints, cardiac system, and reproductive organs.
§ For norepinephrine, there were 329 patients in the norepinephrine group and 344 in the vasopressin group. For epinephrine, there were  
23 patients in the norepinephrine group and 27 in the vasopressin group. For dopamine, there were 28 patients in the norepinephrine 
group and 26 in the vasopressin group. For dobutamine, there were 41 patients in the norepinephrine group and 48 in the vasopressin 
group. For milrinone, there were 10 patients in the norepinephrine group and 13 in the vasopressin group. For phenylephrine, there were  
71 patients in the norepinephrine group and 85 in the vasopressin group.
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Appendix). For most of these analyses, there was 
no evidence of a significant interaction between 
illness severity and vasopressin effect. Two of the 
interaction analyses (stratification according to 
quartile of lactate level and according to number 
of vasopressors at baseline) yielded moderately 
significant P values (P = 0.04 for both), suggesting 
a possible advantage of vasopressin in patients 
Table 2. Analysis of the Rates and Risks of Death from Any Cause and Secondary Outcomes.* 
Variable 
Norepinephrine 
Group  
(N = 382)
Vasopressin 
Group  
(N = 396) P Value†
Absolute Risk  
Reduction  
(95% CI)‡
Relative Risk  
(95% CI)§
Adjusted Odds  
Ratio¶
 no./total no. (%) %
Patients who underwent random-
ization and infusion
28-day mortality 150/382 (39.3) 140/396 (35.4) 0.26 3.9 (−2.9 to 10.7) 0.90 (0.75 to 1.08) 0.88 (0.62 to 1.26)
90-day mortality 188/379 (49.6) 172/392 (43.9) 0.11 5.7 (−1.3 to 12.8) 0.88 (0.76 to 1.03) 0.81 (0.57 to 1.16)
Patients who underwent  
randomization
28-day mortality 154/395 (39.0) 144/404 (35.6) 0.33 3.3 (−3.4 to 10.1) 0.91 (0.76 to 1.09)
90-day mortality 194/392 (49.5) 177/400 (44.2) 0.14 5.2 (−1.7 to 12.2) 0.89 (0.77 to 1.04)
median (interquartile range)
Days alive‖
Free of organ dysfunction
Cardiovascular 17 (0–24) 19 (0–24) 0.58
Vasopressor use** 17 (0–24) 19 (0–24) 0.61
Respiratory 2 (0–14) 3.5 (0–16) 0.15
Ventilation†† 6 (0–20) 8.5 (0–20) 0.24
Renal 18.5 (3–28) 21.5 (4–28) 0.54
Renal-replacement therapy 23 (5–28) 25 (6–28) 0.64
Hepatic 24.5 (3–28) 25 (5–28) 0.80
Hematologic 23 (3–28) 24 (5–28) 0.48
Neurologic 15 (0–24) 15 (0–24) 0.57
Free of any organ failure 0 (0–6) 0 (0–9) 0.14
Free of the systemic inflammatory 
response syndrome‡‡
6 (0–15) 6 (0–18) 0.21
Free of corticosteroid use 13.5 (1–24) 16 (1–25) 0.33
Length of stay (days) 
In ICU 16 (8–32) 15 (7–29) 0.14
In hospital 26 (15–53) 27 (13–52) 0.23
* Patients were analyzed in the treatment group to which they were assigned at randomization. 
† Two-sided P values are based on Pearson’s chi-square test.
‡ The absolute risk reduction is the mortality rate in the norepinephrine group minus the mortality rate in the vasopressin group.
§ The relative risk is the mortality rate in the vasopressin group divided by the mortality rate in the norepinephrine group.
¶ Multivariate logistic-regression analysis incorporated all significant covariates from Table 1. Baseline information was not available on the 
patients who underwent randomization but did not undergo infusion. Therefore, an adjusted analysis of the randomized, intention-to-treat 
population was not possible.
‖ Organ dysfunction for each organ system was considered to be present during each 24-hour period if there was evidence of moderate,  
severe, or extreme organ dysfunction according to the Brussels criteria16 (see the Supplementary Appendix). A low score indicates more 
severe organ dysfunction and fewer days alive while free of organ dysfunction. P values are based on the Wilcoxon rank-sum test.
** Vasopressor use was defined as 5 μg or more of dopamine per kilogram per minute or any dose of norepinephrine, epinephrine, or phen-
ylephrine.
†† Ventilation was defined as intubation and positive-pressure ventilation.
‡‡ Freedom from the systemic inflammatory response syndrome was defined as freedom from two or more of the four diagnostic criteria.
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with less severe shock (Table 3 in the Supplemen-
tary Appendix).
Discussion
In this multicenter, randomized, double-blind trial 
of low-dose vasopressin as compared with norepi-
nephrine in patients with septic shock, we were not 
able to demonstrate any significant difference in 
the 28-day mortality rate (35.4% in the vasopres-
sin group vs. 39.3% in the norepinephrine group, 
P = 0.26). We were also unable to demonstrate any 
significant difference between the two study groups 
in 90-day mortality or the rate of organ dysfunc-
tion. There was no difference in the rates of seri-
ous adverse events between the vasopressin and 
norepinephrine groups. Infusions of low-dose va-
sopressin (0.03 U per minute) increased plasma va-
sopressin levels to approximately 70 to 100 pmol 
per liter from extremely low baseline vasopressin 
levels (median, 3.2 pmol per liter). Consistent with 
at least 14 previous trials in humans10-14,20-28 of 
low-dose vasopressin (≤0.1 U per minute), vaso-
pressin infusion allowed a rapid decrease in the 
total norepinephrine dose while maintaining mean 
arterial pressure.10-12,29
Our study was prospectively powered to detect 
an absolute difference in mortality of 10% from an 
expected 60%. However, the observed mortality 
rates in both the vasopressin and norepinephrine 
groups were considerably lower than those in pre-
vious studies, perhaps because of overall improve-
ments in the care of patients who have septic 
shock. Nonetheless, our data exclude with 95% 
confidence a harm associated with the use of va-
sopressin that was greater than 2.9% or a ben-
efit that was greater than 10.7%.
The overall rates of serious adverse events were 
approximately 10% each in the vasopressin and 
norepinephrine groups. Previous studies raised 
the possibility that vasopressin infusion may in-
crease the incidence of cardiac arrest.29 In con-
trast, we found that of 11 cardiac arrests reported 
in this study, 8 occurred in the norepinephrine 
group and 3 occurred in the vasopressin group. 
Our selection of a low dose of vasopressin (0.03 U 
per minute) and careful exclusion of patients who 
had acute coronary syndromes or severe heart fail-
ure could account for the lack of adverse cardio-
vascular effects of vasopressin infusion. If vaso-
pressin becomes routine therapy and is given at 
higher doses or to patients with septic shock who 
have coexisting heart disease, the adverse reac-
tions to vasopressin could be increased. Other re-
ported adverse effects of vasopressin and norepi-
nephrine include decreased cardiac output,11,14,29 
mesenteric ischemia,21,30 hyponatremia (with va-
sopressin only), skin necrosis,31 and digital ische-
mia.32 More patients in the vasopressin group 
than in the norepinephrine group had digital ische-
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Figure 2. Kaplan–Meier Survival Curves for Patients Who Underwent Ran-
domization and Infusion.
The dashed vertical line marks day 28. P values were calculated with the 
use of the log-rank test.
Table 3. Serious Adverse Events in Patients Who Had Septic Shock.
Variable
Norepinephrine 
Group (N = 382)
Vasopressin 
Group (N = 396) P Value*
no. (%)
At least one serious adverse 
event
40 (10.5) 41 (10.3) 1.00
Acute myocardial infarction 
or ischemia
7 (1.8) 8 (2.0) 1.00
Cardiac arrest 8 (2.1) 3 (0.8) 0.14
Life-threatening arrhythmia 6 (1.6) 8 (2.0) 0.79
Acute mesenteric ischemia 13 (3.4) 9 (2.3) 0.39
Hyponatremia† 1 (0.3) 1 (0.3) 1.00
Digital ischemia 2 (0.5) 8 (2.0) 0.11
Cerebrovascular accident 1 (0.3) 1 (0.3) 1.00
Other‡ 2 (0.5) 5 (1.3) 0.45
* Two-sided P values are based on Fisher’s exact test.
† Hyponatremia was defined as a serum sodium level of less than 130 mmol 
per liter.
‡ Other events include acute hepatitis, agranulocytosis, pulmonary embolism, 
seizures, drug error, and two cases of drug extravasation from the central ve-
nous catheter.
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mia; one patient in the vasopressin group re-
quired surgical intervention.
Our secondary hypothesis was that the benefi-
cial effects of vasopressin as compared with nor-
epinephrine would be more pronounced in the 
subgroup of patients with more severe septic 
shock. No significant interaction between treat-
ment group and shock-severity subgroup (as de-
fined a priori) was shown. Some of the analyses 
we performed suggested that vasopressin may be 
more beneficial in patients with less severe septic 
shock. However, the statistical significance of 
these observations is uncertain, especially because 
of the many statistical tests performed, and this 
finding should be considered only as a hypoth-
esis-generating concept to be tested in future 
trials.33
Several limitations of our trial should be men-
tioned. The vasopressin was infused over a set 
range of doses, and we did not measure vasopres-
sin levels as a guide to the dose or the duration of 
infusion. In addition, in this trial the mean arte-
rial pressure at baseline was 72 to 73 mm Hg, 
essentially making this a study of the effects of 
low-dose vasopressin as a “catecholamine-sparing 
drug,” not an evaluation of vasopressin in patients 
with catecholamine-unresponsive refractory shock. 
The mean time from meeting the criteria for study 
entry to infusion of the study drug (12 hours) was 
greater than the period that Rivers and col-
leagues4 identified as being important in early 
goal-directed therapy (6 hours), which may be one 
reason that we did not find a benefit of vasopres-
sin as compared with norepinephrine.
In summary, we evaluated the effect of low-
dose vasopressin (0.03 U per minute) when used 
in conjunction with catecholamine vasopressors 
in patients with septic shock. We did not find a 
significant reduction in mortality rates with va-
sopressin.
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Table 4. Rates and Risks of Death from Any Cause According to the Severity of Shock.*
Stratum
Norepinephrine 
Group
Vasopressin  
Group P Value†
Absolute Risk Reduction 
(95% CI)
Relative Risk  
(95% CI)
no./total no. (%) %
More severe septic shock 
28-day mortality 85/200 (42.5) 88/200 (44.0) 0.76 −1.5 (−11.2 to 8.2) 1.04 (0.83 to 1.3)
90-day mortality 105/199 (52.8) 103/199 (51.8) 0.84 1.0 (−8.8 to 10.8) 0.98 (0.81 to 1.18)
Less severe septic shock 
28-day mortality 65/182 (35.7) 52/196 (26.5) 0.05 9.2 (−0.1 to 18.5) 0.74 (0.55 to 1.01)
90-day mortality 83/180 (46.1) 69/193 (35.8) 0.04 10.4 (0.4 to 20.3) 0.78 (0.61 to 0.99)
* Patients with more severe septic shock were defined as those who required at least 15 μg of norepinephrine per minute or the equivalent at 
the time of randomization. Those with less severe septic shock were defined as those who required 5 to 14 μg of norepinephrine per minute 
or the equivalent at the time of randomization.
† Two-sided P values are based on Pearson’s chi-square test.
APPENDIX
The following persons and institutions participated in the Vasopressin and Septic Shock Trial (VASST): Writing Committee — J.A. Rus-
sell (chair), K.R. Walley, A.C. Gordon, C. Holmes, J.T. Granton, P.C. Hébert, D.J. Cooper, S. Mehta, J. Singer, D.J. Cook, J.J. Presneill, 
M.M. Storms; Executive Committee — J.A. Russell (chair), K.R. Walley, C.L. Holmes, J.T. Granton, P.C. Hébert, D.J. Cooper, S. Mehta, 
J. Singer, A.C. Gordon, M.M. Storms (project coordinator), S. Jones (administrative assistant); Management Committee — J.A. Russell 
(chair), M.M. Storms (project coordinator), K.R. Walley, C.L. Holmes, J. Singer, A.C. Gordon, S. Jones (administrative assistant); Data 
Safety and Monitoring Board — G.R. Bernard (chair), A.S. Slutsky, G.A Wells; Canadian Institutes of Health Research — A. Gasparini; 
Data Management — J. Singer, B. Savage, D. Ayers, R. Woods, K. Wu, M. Maralit; Monitoring — L. Smith, K. Foley, A. Suri, M. Stein-
berg, B. Howe, P. Galt, A. Higgins, M.M. Storms; Laboratory — M.E. LeBlanc, A.M. Sutherland, A. Sham, A. McLeod; Clinical Centers 
and Investigators: Canada — British Columbia: St. Paul’s Hospital — J.A. Russell, K.R. Walley, D.R. Dorscheid, M. Hameed, L. Lazosky, 
S. Helderweirt, K. Foley, C. Honeyman, T. Terins; Vancouver General Hospital — D. Chittock, J. Ronco, L. Smith, S. Logie; Royal Jubilee 
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Hospital — G. Wood, F. Auld; Kelowna General Hospital — C. Holmes, V. Stedham, M. Mantle, L. Fox, G.D. McCauley, J.D. Rolf, C. Er-
bacher; Richmond General Hospital — G. Martinka, S. Goulding, S. Silverwood, L. Leung; Royal Columbian Hospital — S. Keenan, J. Murray, 
M. Van Osch; Manitoba: St. Boniface Hospital — B. Light, M. Dominique; Winnipeg Health Science Centre — P. Gray, R. Stimpson, S. Rosser, 
D. Bell, W. Janz; Ontario: Ottawa Hospital, General Campus — P.C. Hébert, T. McArdle, I. Watpool; University Health Network–Toronto General 
& Toronto Western Hospitals — J.T. Granton, M. Steinberg, A. Matte-Martyn; St. Joseph’s Hospital — D.J Cook, E. McDonald, F. Clarke, A. 
Tkaczyk, N. Zytaruk; Mount Sinai Hospital — S. Mehta, T. Stewart, A. Suri, C. Martinez-Motta, R. MacDonald, V. Sivanantham; Ottawa 
Hospital, Civic Campus — R. Hodder, J. Foxall, M. Lewis; St. Michael’s Hospital — M. Ward, C. Dos Santos, J. Friedrich, D. Scales, O. Smith, 
I. DeCampos, A. Richards, H. Michalopoulos, U. Bakshi; Sunnybrook and Women’s College Health Science Centre — W. Sibbald (deceased), T. 
Smith, K. Code, B. Bojilov, C. Dale, M. Keogh; Hamilton Health Sciences Centre — M. Meade, L. Hand; London Health Sciences Centre — C. 
Martin, J. Kehoe, V. Binns; Sudbury Regional Hospital — M. Mehta, M. McGuire; Charles LeMoyne Hospital — G. Poirier, L. Provost; Hôtel-Dieu 
Grace Hospital — J. Muscedere, C. Diemer; Australia — Victoria: Alfred Hospital — D.J. Cooper, V. Pellegrino, A. Hilton, S. Morrison, S. 
Vallance, K. Moulden, C. Harry; Royal Melbourne Hospital — J.J. Presneill, M.S. Robertson, J.F. Cade, B.D. Howe, D.K. Barge, C.A. Boyce, 
F. Healy; Monash Medical Centre — C. Wright, D. Weyandt, J. Barrett, C. Walker, P. Galt, S. Burton; Western Australia: Royal Perth Hospital 
— G. Dobb, S. Perryman, J. Chamberlain, L. Thomas; South Australia: Flinders Medical Centre — A. Bersten, L. Daly, T. Hunt, D. Wood; 
United States — Phoenix, AZ: Mayo Clinic Hospital — B. Patel, J. Larson, M. Rady, G. LeBrun, E. Boyd, R. Rush.
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